Penn Capital Management Company LLC purchased a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) during the third quarter, HoldingsChannel reports. The firm purchased 4,297 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,009,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of JAZZ. AEGON ASSET MANAGEMENT UK Plc bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth approximately $2,007,000. AlphaCore Capital LLC increased its holdings in shares of Jazz Pharmaceuticals by 55.4% during the 3rd quarter. AlphaCore Capital LLC now owns 1,987 shares of the specialty pharmaceutical company’s stock worth $460,000 after acquiring an additional 708 shares during the last quarter. Retirement Systems of Alabama increased its holdings in shares of Jazz Pharmaceuticals by 7.6% during the 3rd quarter. Retirement Systems of Alabama now owns 171,801 shares of the specialty pharmaceutical company’s stock worth $39,775,000 after acquiring an additional 12,138 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Jazz Pharmaceuticals by 1,326.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 46,056 shares of the specialty pharmaceutical company’s stock valued at $10,732,000 after acquiring an additional 42,827 shares during the period. Finally, Point Nemo Capital LLC bought a new stake in Jazz Pharmaceuticals in the 3rd quarter valued at $1,345,000. Institutional investors own 89.14% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have issued reports on JAZZ. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $220.00 price target on shares of Jazz Pharmaceuticals in a report on Monday. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. JPMorgan Chase & Co. upped their price objective on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Royal Bank Of Canada increased their price objective on shares of Jazz Pharmaceuticals from $296.00 to $305.00 and gave the company an “outperform” rating in a research report on Tuesday, November 3rd. Finally, UBS Group raised their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research note on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $293.00.
View Our Latest Research Report on JAZZ
Insiders Place Their Bets
In other Jazz Pharmaceuticals news, EVP Neena Patil sold 1,200 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the sale, the executive vice president owned 47,671 shares of the company’s stock, valued at $11,485,850.74. The trade was a 2.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce Cozadd sold 68,808 shares of the business’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $235.95, for a total transaction of $16,235,247.60. Following the completion of the sale, the director directly owned 357,567 shares of the company’s stock, valued at $84,367,933.65. This represents a 16.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 171,342 shares of company stock worth $41,420,491. 4.10% of the stock is currently owned by insiders.
Jazz Pharmaceuticals Stock Up 0.8%
JAZZ opened at $245.43 on Wednesday. Jazz Pharmaceuticals PLC has a fifty-two week low of $132.10 and a fifty-two week high of $266.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82. The company has a market capitalization of $15.75 billion, a P/E ratio of 83.48, a P/E/G ratio of 0.44 and a beta of 0.38. The stock has a fifty day moving average of $229.26 and a 200-day moving average of $218.48.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last announced its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.88%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the business posted $8.13 earnings per share. Jazz Pharmaceuticals’s quarterly revenue was up 10.4% on a year-over-year basis. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 11.08 EPS for the current year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
